Oligodendroglioma - Pipeline Review, H2 2018

Oligodendroglioma - Pipeline Review, H2 2018


  • Products Id :- GMDHC10796IDB
  • |
  • Pages: 155
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Oligodendroglioma-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Oligodendroglioma-Pipeline Review, H2 2018, provides an overview of the Oligodendroglioma (Oncology) pipeline landscape.

Oligodendroglioma is a type of glioma (primary glial brain tumor). They often contain mineral deposits (called calcifications), areas of hemorrhage, and/or cysts. The most common symptoms are seizures, headaches, and personality changes. Other symptoms vary by location and size of the tumor. Treatment includes chemotherapy surgery and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Oligodendroglioma-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Oligodendroglioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Oligodendroglioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Oligodendroglioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 9, 7 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 1 molecules, respectively.

Oligodendroglioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Oligodendroglioma (Oncology).

- The pipeline guide reviews pipeline therapeutics for Oligodendroglioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Oligodendroglioma (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Oligodendroglioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Oligodendroglioma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Oligodendroglioma (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Oligodendroglioma (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

Introduction 4

Oligodendroglioma-Overview 5

Oligodendroglioma-Therapeutics Development 6

Oligodendroglioma-Therapeutics Assessment 12

Oligodendroglioma-Companies Involved in Therapeutics Development 20

Oligodendroglioma-Drug Profiles 28

Oligodendroglioma-Dormant Projects 150

Oligodendroglioma-Discontinued Products 151

Appendix 152

List of Figures

Number of Products under Development for Oligodendroglioma, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

List of Tables

Number of Products under Development for Oligodendroglioma, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Oligodendroglioma-Pipeline by AbbVie Inc, H2 2018

Oligodendroglioma-Pipeline by AlfaSigma SpA, H2 2018

Oligodendroglioma-Pipeline by AngioChem Inc, H2 2018

Oligodendroglioma-Pipeline by Astellas Pharma Inc, H2 2018

Oligodendroglioma-Pipeline by Bayer AG, H2 2018

Oligodendroglioma-Pipeline by Boehringer Ingelheim GmbH, H2 2018

Oligodendroglioma-Pipeline by Bristol-Myers Squibb Co, H2 2018

Oligodendroglioma-Pipeline by Eli Lilly and Co, H2 2018

Oligodendroglioma-Pipeline by GtreeBNT Co Ltd, H2 2018

Oligodendroglioma-Pipeline by Immatics Biotechnologies GmbH, H2 2018

Oligodendroglioma-Pipeline by Ipsen SA, H2 2018

Oligodendroglioma-Pipeline by Northwest Biotherapeutics Inc, H2 2018

Oligodendroglioma-Pipeline by Novartis AG, H2 2018

Oligodendroglioma-Pipeline by Pfizer Inc, H2 2018

Oligodendroglioma-Pipeline by Taiho Pharmaceutical Co Ltd, H2 2018

Oligodendroglioma-Pipeline by TheraBiologics Inc, H2 2018

Oligodendroglioma-Pipeline by Tocagen Inc, H2 2018

Oligodendroglioma-Dormant Projects, H2 2018

Oligodendroglioma-Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

AbbVie Inc

AlfaSigma SpA

AngioChem Inc

Astellas Pharma Inc

Bayer AG

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Eli Lilly and Co

GtreeBNT Co Ltd

Immatics Biotechnologies GmbH

Ipsen SA

Northwest Biotherapeutics Inc

Novartis AG

Pfizer Inc

Taiho Pharmaceutical Co Ltd

TheraBiologics Inc

Tocagen Inc

Oligodendroglioma Therapeutic Products under Development, Key Players in Oligodendroglioma Therapeutics, Oligodendroglioma Pipeline Overview, Oligodendroglioma Pipeline, Oligodendroglioma Pipeline Assessment

select a license
Single User License
USD 2000 INR 142600
Site License
USD 4000 INR 285200
Corporate User License
USD 6000 INR 427800

NEWSLETTER BY CATEGORY




Testimonials

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com